Drive Profitable Growth Investor Presentation February 2026 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, intentions, plans, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statem ...

Core Insights - Orthofix Medical Inc. reported strong financial results for Q4 and full-year 2025, highlighting significant operational progress and robust free cash flow generation [1][2] Financial Results Overview Fourth Quarter 2025 - Reported net sales of $219.9 million, a 2% increase compared to Q4 2024, with pro forma net sales of $218.6 million, reflecting a 3.1% increase on a constant currency basis [1][2] - Non-GAAP pro forma adjusted EBITDA was $29.2 million, representing a margin of 13.4%, an increase from 11.1% in Q4 2024 [2][3] - The company achieved a free cash flow of $16.8 million in Q4 2025, contributing to a positive full-year free cash flow of $3.1 million, excluding M6-related restructuring charges [1][2] Full-Year 2025 - Total reported net sales reached $822.3 million, a 2.9% increase from 2024, with pro forma net sales of $811.9 million, indicating a 4.1% increase on a constant currency basis [2][3] - Gross margins were reported at 68.8%, with non-GAAP pro forma adjusted gross margins at 71.6% [2][3] - The net loss for the year was $(92.2) million, or $(2.33) per share, an improvement from a net loss of $(126.0) million in 2024 [2][3] Business Outlook - For 2026, the company expects net sales to range between $850 million to $860 million, indicating a year-over-year pro forma constant currency growth of approximately 5.5% [2][3] - Non-GAAP adjusted EBITDA is projected to be between $95 million to $98 million, reflecting a margin expansion of 70 basis points compared to 2025 [2][3] - The company aims for positive free cash flow in 2026, excluding potential legal settlements [2][3] Three-Year Financial Targets - Orthofix updated its three-year financial targets, projecting positive free cash flow generation from 2026 through 2028 and mid-teens non-GAAP adjusted EBITDA as a percentage of net sales by 2028 [2][3] - The company anticipates a compound annual growth rate (CAGR) of 6.5% to 7.5% in net sales from 2026 to 2028 [2][3]

Clear Course for Profitable Growth 1Q 2025 Earnings Call May 6, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, intentions, plans, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looki ...